机译:The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study
Actelion Pharmaceuticals Ltd;
Mater Misericordiae University Hospital;
DIMES, University of Bologna and IRCCS, S. Orsola University HospitalUniversity of Giessen and Marburg Lung Center,Giessen, Germany, member of the German Center forCedars‐Sinai Medical CenterDivision of Cardiology,Medical University of ViennaDepartment of Respiratory Medicine,Hannover Medical School and German Center for Lung ResearchUniversity of MichiganDivision of Pulmonary and Critical Care Medicine,University of CaliforniaH?pital Universitaire de Bicêtre,Université Paris‐SudHeart Center,University Hospital Cologne, and Cologne Cardiovascular Research Center (CCRC)University of California Los AngelesUT Southwestern Medical Center;
Comorbidities; Pulmonary arterial hypertension; Selexipag; Randomized controlled trial; Post hoc analysis;